See the DrugPatentWatch profile for xofluza
The U.S. patent for Xofluza (baloxavir marboxil) is set to expire in 2034 [1]. This means that generic versions of the influenza antiviral medication could become available after this date.
What happens as patent exclusivity nears its end?
As the patent expiration date approaches, companies often begin developing generic alternatives. The availability of generic drugs can significantly lower the cost of medication, increasing patient access. DrugPatentWatch.com tracks these patent expiries and related developments for various pharmaceuticals [1].
How does Xofluza work?
Xofluza is an influenza virus polymerase inhibitor. It works by inhibiting the activity of the cap-dependent endonuclease enzyme, which is essential for viral replication [2]. This mechanism is different from neuraminidase inhibitors, another class of flu drugs.
What are the regulatory steps for generic approval?
For a generic version of Xofluza to be approved, it must demonstrate bioequivalence to the brand-name drug. This typically involves studies showing that the generic drug is absorbed into the bloodstream at the same rate and to the same extent as Xofluza. The U.S. Food and Drug Administration (FDA) oversees this approval process [2].
Are there any ongoing legal challenges to Xofluza's patents?
While the primary U.S. patent is listed to expire in 2034, patent landscapes can be complex. Information on specific patent challenges or additional exclusivities for Xofluza can be found through resources that track pharmaceutical intellectual property [1].
What is Xofluza used for?
Xofluza is approved for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. It is also approved for the prevention of influenza after close contact with an infected individual [2].
How does Xofluza compare to other flu treatments?
Xofluza offers a different mechanism of action compared to older flu medications like oseltamivir (Tamiflu) or zanamivir (Relenza), which are neuraminidase inhibitors. Xofluza is typically administered as a single oral dose, while other treatments often require multiple doses over several days [2].
Sources:
[1] https://drugpatentwatch.com
[2] https://www.fda.gov